Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2019.16326
Abstract: This cohort study describes patterns of development, management strategies, and long-term vascular consequences of hypertension associated with ibrutinib in the non–clinical trial setting. read more here.
Keywords: hypertension patients; patients treated; ibrutinib chronic; treated ibrutinib ... See more keywords
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04094-3
Abstract: Background Ibrutinib therapy is associated with an increased risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL). Risk assessment tools and outcomes of AF in these patients are not well described. Methods We performed… read more here.
Keywords: atrial fibrillation; risk; treatment; treated ibrutinib ... See more keywords
Apoptosis Resistance and NOTCH1 Mutations Impair Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.261.261
Abstract: Ibrutinib, an oral, selective inhibitor of Bruton9s tyrosyne kinase (BTK), demonstrated superior overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) compared with chemoimmunotherapy in CLL both in first line and in relapsed/refractory… read more here.
Keywords: pfs; patients treated; bax bcl; treated ibrutinib ... See more keywords
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2018026401
Abstract: The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein. The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with… read more here.
Keywords: relapsed refractory; cell; treated ibrutinib; double expressor ... See more keywords
Pre-Existing Cardiovascular Disease Increases Risk of Atrial Arrhythmia in Cancer Patients Treated with Ibrutinib
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the American College of Cardiology"
DOI: 10.21203/rs.3.rs-401031/v1
Abstract: Background: Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flutter). It is known that patients with… read more here.
Keywords: arrhythmia; cardiovascular disease; treated ibrutinib; atrial arrhythmia ... See more keywords
Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
Sign Up to like & getrecommendations! Published in 2023 at "Medicina"
DOI: 10.3390/medicina59020324
Abstract: Background and Objectives: The treatment of chronic lymphocytic leukemia (CLL) has acquired new targeted therapies. In clinical trials, ibrutinib improved outcomes safely. Real-world data called for a reappraisal of ibrutinib strategies. We report on a… read more here.
Keywords: single center; lymphocytic leukemia; chronic lymphocytic; treated ibrutinib ... See more keywords